Shelton Capital Management Sells 37,700 Shares of DaVita Inc. $DVA

Shelton Capital Management reduced its stake in DaVita Inc. (NYSE:DVA) by 52.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 33,854 shares of the company’s stock after selling 37,700 shares during the period. Shelton Capital Management’s holdings in DaVita were worth $4,823,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of DVA. Norges Bank acquired a new position in DaVita during the second quarter worth $32,986,000. Doma Perpetual Capital Management LLC increased its position in shares of DaVita by 172.3% during the 1st quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock worth $44,110,000 after purchasing an additional 182,476 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in DaVita during the 2nd quarter valued at about $21,554,000. Northern Trust Corp boosted its position in DaVita by 20.2% in the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after buying an additional 149,858 shares in the last quarter. Finally, Nuveen LLC bought a new stake in DaVita during the first quarter worth about $20,218,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Down 0.2%

Shares of DVA stock opened at $119.44 on Tuesday. DaVita Inc. has a 12 month low of $113.97 and a 12 month high of $179.60. The firm has a market cap of $8.43 billion, a price-to-earnings ratio of 12.30, a PEG ratio of 0.91 and a beta of 1.13. The stock has a 50-day moving average price of $124.78 and a 200 day moving average price of $133.47.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a return on equity of 815.62% and a net margin of 5.80%.The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. During the same quarter in the prior year, the firm earned $2.59 EPS. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Sell-side analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on DVA shares. Zacks Research raised DaVita from a “strong sell” rating to a “hold” rating in a report on Friday. Barclays reduced their price objective on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 30th. Truist Financial set a $140.00 target price on DaVita in a research note on Tuesday, October 14th. Cowen reiterated a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. Finally, Bank of America lowered their price objective on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Six analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $148.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.